Is there a tirzepatide pill? What the evidence says

What clinical evidence actually exists for oral tirzepatide?

The interest in tirzepatide as a pill is understandable. The injectable form has produced some of the most striking weight-loss results seen in a phase 3 programme. In SURMOUNT-1, published in the New England Journal of Medicine, participants taking 15 mg tirzepatide lost an average of around 20–21% of their body weight over 72 weeks, a figure that helped drive enormous public interest in the molecule. Naturally, people want to know whether that same effect could come in a form they swallow rather than inject, and our page on tirzepatide in pill form walks through where the research currently stands.

Early-phase trials of an oral tirzepatide formulation do exist. Eli Lilly published phase 1 data showing the drug can be absorbed when taken orally, and phase 2 work is ongoing. But absorbing a large peptide molecule through the gut wall is chemically harder than absorbing a small-molecule drug, and the dose requirements, bioavailability and side-effect profile for an oral version are still being characterised. No phase 3 results have been published. No submission to the MHRA for an oral tirzepatide licence has been publicly announced. The evidence base that would support prescribing it simply does not exist yet in the UK regulatory sense.

For now, the clinical story of tirzepatide is an injectable one. Anyone reading confident claims about a tirzepatide pill already on the market should treat those claims with real caution, the MHRA Yellow Card scheme exists precisely so that patients and clinicians can flag unlicensed or suspect products.

The oral GLP-1 option that is licensed in the UK right now

There is an important distinction to draw here. While tirzepatide in pill form remains unlicensed, the UK does now have a licensed oral GLP-1 weight-loss medicine. On 11 June 2026 the MHRA approved the Wegovy tablet (oral semaglutide) making the UK the first country in Europe to licence it for weight management. You can read more about how that compares to the Mounjaro injection if you are weighing up your options.

The Wegovy tablet works via a single GLP-1 receptor pathway, whereas tirzepatide activates both GLP-1 and GIP receptors. In the OASIS 4 trial, participants using the 25 mg oral semaglutide maintenance dose lost an average of around 13.6% of body weight over 64 weeks; among those who adhered fully to treatment, that figure reached approximately 17%. It is a meaningfully different molecule from tirzepatide, and the two are not interchangeable, but for someone who strongly prefers not to inject, it is a real, licensed alternative rather than a theoretical one.

A question our prescribers hear most weeks is whether the tablet will eventually replace the injection entirely. The honest clinical view is that different formulations suit different people, and the evidence for the injectable forms (both Mounjaro and Wegovy) is considerably more mature.

What does 'unlicensed' actually mean for patients considering a pill?

A medicine is unlicensed in the UK when the MHRA has not evaluated and approved it for a specific use. That evaluation covers safety, quality and efficacy, the full data package a manufacturer must submit. When tirzepatide is described as available only as an injection, that is not a commercial preference; it reflects the evidence submitted and approved. You can see the detail of what Mounjaro is authorised for, including the mechanism and eligible populations, in NICE technology appraisal TA1026, published in December 2024.

The practical implication for patients is straightforward. Sellers claiming to offer tirzepatide pills or oral tirzepatide capsules for weight loss in the UK are selling a product with no MHRA approval, which means no verified manufacturing standards, no confirmed dosing and no clinical oversight of your response. The MHRA has already seized large volumes of counterfeit injectable weight-loss pens; the same risks apply to any unlicensed oral form.

If you are specifically looking for whether tirzepatide comes in a pill form that you can legally access in the UK, the current answer remains no. That may change as clinical development continues, and the research is genuinely promising, but promising data and a licensed medicine are two different things. In the meantime, exploring what is approved and clinically supervised is the safer path. You can look at the full range of licensed weight-loss treatments available through a regulated UK pharmacy, including both injectable and oral options, to find what fits your circumstances. If you want to understand more about the injectable form while you wait to see how the pipeline develops, our Mounjaro overview covers the evidence in full.